CN113368209A - New application of astragalus-leech capsule in preparation of medicine for treating primary hypertension - Google Patents
New application of astragalus-leech capsule in preparation of medicine for treating primary hypertension Download PDFInfo
- Publication number
- CN113368209A CN113368209A CN202110641504.1A CN202110641504A CN113368209A CN 113368209 A CN113368209 A CN 113368209A CN 202110641504 A CN202110641504 A CN 202110641504A CN 113368209 A CN113368209 A CN 113368209A
- Authority
- CN
- China
- Prior art keywords
- astragalus
- parts
- leech
- capsule
- new use
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 99
- 239000003814 drug Substances 0.000 title claims abstract description 68
- 208000007530 Essential hypertension Diseases 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims description 9
- 241000545744 Hirudinea Species 0.000 claims abstract description 46
- 235000006533 astragalus Nutrition 0.000 claims abstract description 46
- 241001061264 Astragalus Species 0.000 claims abstract description 44
- 210000004233 talus Anatomy 0.000 claims abstract description 44
- 244000144730 Amygdalus persica Species 0.000 claims abstract description 14
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 14
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 14
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 14
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 14
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 14
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 14
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 14
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 14
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 14
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 14
- 240000009138 Curcuma zedoaria Species 0.000 claims abstract description 14
- 235000006040 Prunus persica var persica Nutrition 0.000 claims abstract description 14
- 241001289529 Fallopia multiflora Species 0.000 claims abstract description 13
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 12
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 12
- 240000000171 Crataegus monogyna Species 0.000 claims abstract 4
- 230000035488 systolic blood pressure Effects 0.000 claims description 26
- 229940079593 drug Drugs 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 241000131329 Carabidae Species 0.000 claims description 10
- 230000035790 physiological processes and functions Effects 0.000 claims description 10
- 238000005303 weighing Methods 0.000 claims description 7
- 230000033228 biological regulation Effects 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 201000005577 familial hyperlipidemia Diseases 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 230000004584 weight gain Effects 0.000 claims description 3
- 235000019786 weight gain Nutrition 0.000 claims description 3
- 241000045403 Astragalus propinquus Species 0.000 claims description 2
- 230000037323 metabolic rate Effects 0.000 claims description 2
- 210000000582 semen Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 abstract description 26
- 210000004369 blood Anatomy 0.000 abstract description 26
- 206010020772 Hypertension Diseases 0.000 abstract description 19
- 230000006870 function Effects 0.000 abstract description 8
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 8
- 241000721047 Danaus plexippus Species 0.000 abstract description 7
- 235000003405 Curcuma zedoaria Nutrition 0.000 abstract description 4
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 abstract description 4
- 235000019509 white turmeric Nutrition 0.000 abstract description 4
- 238000012360 testing method Methods 0.000 abstract description 2
- 235000014375 Curcuma Nutrition 0.000 abstract 1
- 244000164480 Curcuma aromatica Species 0.000 abstract 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 abstract 1
- 230000007102 metabolic function Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 59
- 230000036772 blood pressure Effects 0.000 description 23
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 14
- 229960001138 acetylsalicylic acid Drugs 0.000 description 14
- 230000002503 metabolic effect Effects 0.000 description 12
- 230000008859 change Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 241001092040 Crataegus Species 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- 230000009471 action Effects 0.000 description 9
- 230000003276 anti-hypertensive effect Effects 0.000 description 8
- 210000002700 urine Anatomy 0.000 description 8
- 238000000034 method Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 230000001603 reducing effect Effects 0.000 description 5
- 239000003643 water by type Substances 0.000 description 5
- 238000010171 animal model Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000004051 gastric juice Anatomy 0.000 description 4
- 230000001631 hypertensive effect Effects 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000007938 effervescent tablet Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000000513 principal component analysis Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 3
- 238000011706 wistar kyoto rat Methods 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 240000001341 Reynoutria japonica Species 0.000 description 2
- 235000018167 Reynoutria japonica Nutrition 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000007718 Stable Angina Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010010164 Hypertension complications Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108010022337 Leucine Enkephalin Proteins 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 206010041956 Stasis syndrome Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229940127282 angiotensin receptor antagonist Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 208000005634 blind loop syndrome Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000007213 cerebrovascular event Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000011616 hypertension animal model Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- URLZCHNOLZSCCA-UHFFFAOYSA-N leu-enkephalin Chemical compound C=1C=C(O)C=CC=1CC(N)C(=O)NCC(=O)NCC(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1 URLZCHNOLZSCCA-UHFFFAOYSA-N 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000003012 network analysis Methods 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/902—Sparganiaceae (Bur-reed family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Insects & Arthropods (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a new application of astragalus-leech capsules in preparing a medicament for treating primary hypertension. The astragalus-leech capsule is composed of astragalus, polygonum multiflorum, cassia seed, hawthorn, peach kernel, curcuma zedoary, rhizoma sparganii, leech and ground beeltle, the traditional Chinese medicines in the formula are mutually reinforced and mutually exclusive, and the astragalus-leech capsule conforms to the compatibility principle of 'monarch, minister, assistant and guide' and has the functions of tonifying qi, removing blood stasis and dredging collaterals. Proved by tests, the astragalus-leech capsule can continuously and stably reduce the hypertension and obviously recover the integral metabolic function of an organism, and is an effective medicament for treating the primary hypertension.
Description
Technical Field
The invention relates to a new application of astragalus-leech capsules in preparing a medicament for treating primary hypertension, and belongs to the technical field of application of traditional Chinese medicines.
Background
Essential hypertension is a comprehensive disease which is mainly characterized by the increase of systemic arterial pressure and is caused by the decompensation of the normal blood pressure regulation mechanism of the body under the action of a plurality of acquired environmental factors under a certain genetic background. Essential hypertension accounts for more than 95 percent of total hypertension, is the first risk factor for inducing people to have cardiovascular and cerebrovascular events, effectively controls blood pressure and treats essential hypertension, and is an important medical problem for maintaining human health.
The chemical medicine is the main medicine for clinically treating hypertension at present due to the characteristics of clear action mechanism, quick effect and strong action, and comprises a calcium channel blocker, an angiotensin converting enzyme inhibitor, an angiotensin receptor antagonist, a diuretic and a beta receptor blocker. In order to fully exert the complementary action mechanism of the medicaments to increase the curative effect, ensure that the blood pressure reaches the standard quickly, simultaneously reduce contraindications, malaise and side effects generated in the single medicament application process and keep longer action time, the combined application of the antihypertensive medicaments becomes the basic method of the antihypertensive treatment (revised committee of Chinese guidelines for preventing and treating hypertension in 2018, revised edition of the Chinese guidelines for preventing and treating hypertension in 2018, prevention and treatment of cardiovascular and cerebrovascular diseases, 2019.19(1): 1-44.). Therefore, a fixed-ratio compound preparation (CN105832731B, CN103239723B and CN102008711B) consisting of the medicines is invented.
However, essential hypertension is a complex disease with the combined action of genetic factors and acquired environmental factors, chemical drugs mainly aim at a certain link of pathological changes in the disease process of hypertension, the action path and the action target point are relatively single, although blood pressure can be quickly reduced, blood pressure management is complex, and improvement of hypertension complications cannot be considered. The traditional Chinese medicine regulates the balance of yin and yang and deficiency and excess of qi and blood of an organism, corrects the dysfunction of the organism and treats the hypertension from multiple components, multiple links and multiple targets by treatment based on syndrome differentiation. The prescription (Chinese herbal compound) is a medicine used in the clinical practice of traditional Chinese medicine, and is formed by matching a plurality of traditional Chinese medicines through seven emotions and combination and monarch, minister, assistant and guide; a single Chinese medicine is only the raw material for composing a prescription, and the curative effect of the Chinese medicine is expressed by the prescription according to the syndrome. Therefore, the traditional Chinese medicine compound for treating hypertension has the advantages that on one hand, the prescription function is not only simple addition of the antihypertensive effect of a single traditional Chinese medicine, but also the pharmacological effect is the integral effect of a plurality of traditional Chinese medicines; on the other hand, the traditional Chinese medicines composing the prescription do not all have pharmacological action of reducing blood pressure. The invention discloses a astragalus-leech capsule which has obvious effect of treating essential hypertension, and the prescription is composed of astragalus, leech, ground beeltle, peach kernel, rhizoma sparganii, curcuma zedoary, hawthorn, cassia seed, polygonum multiflorum and other traditional Chinese medicines, and has the functions of tonifying qi, removing blood stasis and realizing a passage.
The astragalus-leech capsule is produced by Haerbin traditional Chinese medicine four factories Limited company, the number of the currently executed national drug standard is WS-5431(B-0431) -2014Z, the approved functions and main indications are tonifying qi, removing blood stasis and dredging collaterals, and the astragalus-leech capsule is clinically used for treating hyperlipidemia, qi deficiency and blood stasis. Through clinical research in recent years, the application range of the astragalus-leech capsule is further expanded, and documents report that the astragalus-leech capsule has satisfactory clinical observation on stable angina pectoris (Penglaangli, and the like, the astragalus-leech capsule has satisfactory clinical observation on stable angina pectoris [ J ]. Heilongjiang traditional Chinese medicine 2014,5: 14-15.). The astragalus leech capsule for treating the essential hypertension and the pharmacological action of lowering the blood pressure are not reported so far, and the invention discovers the new application of the medicament in treating the essential hypertension through experimental research.
The invention discloses a new application of astragalus-leech capsules in a medicament for treating primary hypertension. The astragalus-leech capsule is composed of astragalus, polygonum multiflorum, cassia seed, hawthorn, peach kernel, curcuma zedoary, rhizoma sparganii, leech, ground beeltle and other medicinal ingredients, the traditional Chinese medicines in the formula are mutually reinforced and mutually guided, and the astragalus-leech capsule conforms to the compatibility principle of 'monarch, minister, assistant and guide' and has the functions of tonifying qi, removing blood stasis and dredging collaterals. Proved by tests, the astragalus-leech capsule can continuously and stably reduce the hypertension and remarkably recover the integral metabolic state of an organism, and is an effective medicament for treating the primary hypertension.
Disclosure of Invention
The invention aims to solve the technical problem of providing a new application of astragalus-leech capsules in preparing a medicament for treating primary hypertension in order to overcome the defects of the prior art.
In order to solve the technical problems, the technical scheme adopted by the invention is as follows:
a new use of QIZHI Capsule in preparing medicine for treating essential hypertension is provided.
The astragalus leech capsule can obviously reduce the systolic blood pressure of the essential hypertension.
The astragalus leech capsule can regulate the physiological function of the organism of the essential hypertension.
The physiological functions of the body include weight gain and body metabolic rate regulation (i.e. reduction).
The dosage of the astragalus-leech capsule is 1-4 times of the dosage of the astragalus-leech capsule for clinically treating hyperlipemia.
The astragalus-leech capsule is prepared from the following raw material medicines in parts by weight: 100-400 parts of astragalus membranaceus, 40-160 parts of leech, 75-300 parts of peach kernel, 75-300 parts of polygonum multiflorum, 55-220 parts of curcuma zedoary, 55-220 parts of rhizoma sparganii, 62.5-250 parts of semen cassiae, 62.5-250 parts of hawthorn and 15-60 parts of ground beetle.
The astragalus and leech capsule comprises 200 parts of astragalus, 80 parts of leech, 150 parts of peach kernel, 150 parts of polygonum multiflorum, 110 parts of curcuma zedoary, 110 parts of rhizoma sparganii, 125 parts of cassia seed, 125 parts of hawthorn and 30 parts of ground beetle.
The preparation method of the astragalus-leech capsule comprises the following steps:
step one, weighing leeches, curcuma zedoary and rhizoma sparganii according to a proportion, and crushing into fine powder;
step two, weighing the astragalus, the peach kernel, the polygonum multiflorum, the cassia seed, the hawthorn and the ground beetle according to the proportion, adding water for decocting twice, adding 10 times of water for the first time, adding 8 times of water for the second time, decocting for 2 hours each time, combining decoction liquids, filtering, and concentrating the filtrate to thick paste with the relative density of 1.30-1.35;
and step three, adding the fine powder obtained in the step one into the thick paste obtained in the step two, uniformly mixing, drying at 50-60 ℃, crushing, and encapsulating to obtain the capsule.
The relative density of 1.30 to 1.35 is a relative density at 80 ℃.
The formulation of the astragalus-leech capsule can be replaced by granules, tablets, powder or pills.
The formula of the astragalus-leech capsule for treating primary hypertension disclosed by the invention has the characteristics of mutual reinforcement and mutual guide of traditional Chinese medicines and the principle of monarch, minister, assistant and guide of a prescription. The formula mainly uses the astragalus root which has the effects of tonifying qi and invigorating yang, aims at invigorating qi and promoting blood circulation, removes stasis and removes meridian obstruction, and is a monarch drug; leech and ground beeltle mutually reinforced are used for breaking blood and removing stasis and eliminating mass, zedoary and rhizoma sparganii mutually reinforced are used for breaking blood and removing stasis, eliminating mass and removing stasis, promoting qi circulation and relieving pain, peach kernel breaks blood and removes stasis to moisten dryness, three groups of blood-breaking and stasis-removing medicines are further mutually reinforced and used, and are compatible with qi-tonifying medicine astragalus to treat body deficiency and long-standing retention of blood stasis, and the three groups of blood-breaking and stasis-removing medicines are used as ministerial medicines; the polygonum multiflorum is used for detoxifying, moistening the intestines and relaxing the bowels, the cassia seed is used for clearing heat, moistening the intestines and relaxing the bowels, the hawthorn is used for promoting qi circulation and dissipating blood stasis, the three medicines are mutually reinforced, the turbid descending and detoxifying are carried out, and the three medicines are compatible with the blood-breaking and stasis-dissipating medicines to help dissipate blood stasis and promote tissue regeneration, so that the polygonum multiflorum is used as a messenger medicine; in the formula, the qi tonifying medicine is mutually compatible with a plurality of blood breaking and stasis removing medicines and turbidity lowering and toxin expelling medicines, so that qi and blood are vigorous and moved, blood stasis is removed and collaterals are cleared, qi is tonified without stagnation, blood is broken without hurting vital qi, the medicines are combined to play the functions of tonifying qi, removing blood stasis and dredging collaterals, and the traditional Chinese medicine is used for treating the primary hypertension qi deficiency and blood stasis syndrome.
The invention discloses a new application of astragalus-leech capsules in preparing medicaments for treating primary hypertension, wherein the medicament dosage form of the capsules also comprises one of granules, powder, tablets and pills, and pharmaceutically acceptable auxiliary materials, such as fillers, such as starch, lactose, mannose, chitin, microcrystalline cellulose, sucrose and the like, are added when the dosage forms are prepared in order to realize the dosage forms; disintegrating agents such as starch, microcrystalline cellulose, crospovidone, low-substituted hydroxypropylcellulose, and croscarmellose sodium; lubricants such as magnesium stearate, sodium lauryl sulfate, talc, silica, and the like; binders such as starch slurry, polyvinylpyrrolidone, hydroxypropyl methylcellulose, and the like; saccharin sodium, aspartame, sucrose, sodium cyclamate, etc.
The new application of the astragalus-leech capsule disclosed by the invention in preparing the medicine for treating the primary hypertension has the following remarkable advantages: compared with other patents of the invention, the invention treats the diseases from the aspects of liver-yang hyperactivity (CN1283275C), yin deficiency and yang hyperactivity (CN 103127421B), liver-kidney yin deficiency (CN103989817B), phlegm-damp obstruction in middle (CN105213822B) and the like, and the invention adopts a treatment method of tonifying qi, removing blood stasis and dredging collaterals to form a formula of astragalus-leech capsules aiming at the pathogenesis of primary hypertension and blood stasis; the formula composition of the astragalus-leech capsule conforms to the compatibility theory of 'monarch, minister, assistant and guide' and 'seven emotions and combination' of traditional Chinese medicine prescriptions, the qi-tonifying medicine is matched with the blood-breaking and blood stasis-removing medicine and the turbidity-reducing and toxin-expelling medicine in a mutual guide way, the blood-breaking and blood stasis-removing medicine and the turbidity-reducing and toxin-expelling medicine are matched in a mutual reinforcement way, the qi-tonifying medicine is the monarch, the blood-breaking and blood stasis-removing medicine is the minister, the turbidity-reducing and toxin-expelling medicine is the assistant, the qi-invigorating and blood circulation-promoting, and the stasis-removing and collaterals-dredging, and is used for treating the primary hypertension qi deficiency and blood stasis; animal experiments prove that the astragalus-leech capsule not only can stably and obviously reduce the blood pressure which is more than 30mmHg within the treatment period of 4 weeks, but also can recover the disordered metabolic network and the body weight of a hypertensive rat to normal level, thereby being beneficial to recovering the integral physiological function of the body and embodying the integral treatment advantage of the traditional Chinese medicine.
Drawings
FIG. 1 is a graph showing the trend of the change in systolic blood pressure of rats of the model group (SHR group) and the normal control group (WKY group) at 4-13 weeks of age (P <0.01 compared with the normal control group);
FIG. 2 is a graph showing the trend of change of systolic pressure of rats in 13-17 weeks of age in a model control group (SHR group), a normal control group (WKY group), a high-dose group of astragalus-leech capsules, a medium-dose group of astragalus-leech capsules, a low-dose group of astragalus-leech capsules and an aspirin control group (P is less than 0.01 compared with the normal control group and P is less than 0.01 compared with the model control group);
FIG. 3 is a graph showing the trend of the change in body weight of rats at 4-13 weeks of age in the control group (SHR group) and the normal control group (WKY group) according to the present invention (P <0.01, P <0.05 compared with the normal control group).
FIG. 4 shows the control group (SHR group) and the normal control group (WKY group) of the present inventionThe weight change trend chart of the rats in the astragalus-leech capsule high dose group, the astragalus-leech capsule medium dose group, the astragalus-leech capsule low dose group and the aspirin control group at the age of 13-17 weeks (compared with a normal control group, P is less than 0.01; compared with a model control group,##P＜0.01)。
FIG. 5 is a score chart of PCA analysis of the urine metabolism network of rats with astragalus leech capsules for treating essential hypertension.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more clear, the present invention is further described in detail below with reference to the accompanying drawings and embodiments. The specific embodiments described herein are merely illustrative of the invention and are not intended to be limiting.
Example 1:
a new use of QIZHI Capsule in preparing medicine for treating essential hypertension is provided.
The astragalus leech capsule can obviously reduce the systolic blood pressure of the essential hypertension.
The astragalus leech capsule can regulate the physiological function of the organism of the essential hypertension.
The physiological functions of the organism comprise weight gain and body metabolic network adjustment.
The dosage of the astragalus-leech capsule is 1-4 times of the dosage of the astragalus-leech capsule for clinically treating hyperlipemia.
The astragalus and leech capsule comprises 200 parts of astragalus, 80 parts of leech, 150 parts of peach kernel, 150 parts of polygonum multiflorum, 110 parts of curcuma zedoary, 110 parts of rhizoma sparganii, 125 parts of cassia seed, 125 parts of hawthorn and 30 parts of ground beetle.
The preparation method of the astragalus-leech capsule comprises the following steps:
step one, weighing leeches, curcuma zedoary and rhizoma sparganii according to a proportion, and crushing into fine powder;
step two, weighing the astragalus, the peach kernel, the polygonum multiflorum, the cassia seed, the hawthorn and the ground beetle according to the proportion, adding water for decocting twice, adding 10 times of water for the first time, adding 8 times of water for the second time, decocting for 2 hours each time, combining decoction liquids, filtering, and concentrating the filtrate to thick paste with the relative density of 1.30-1.35;
and step three, adding the fine powder obtained in the step one into the thick paste obtained in the step two, uniformly mixing, drying at 50-60 ℃, crushing, and encapsulating to obtain the capsule.
The relative density of 1.30 to 1.35 is a relative density at 80 ℃.
The formulation of the astragalus-leech capsule can be replaced by granules, tablets, powder or pills.
The effect of the astragalus leech capsule for treating essential hypertension is further illustrated by the following experiments.
The essential Hypertension Rat (SHR) is a hereditary Hypertension model Rat, the pathogenesis and development changes of which are close to those of human beings, and the blood pressure level is higher and stable, so the SHR is an internationally accepted Hypertension animal model at present. The experiment adopts the animal model to research the regulation and control of the astragalus leech capsule on the hypertension, and the antihypertensive effect and the antihypertensive strength of the astragalus leech capsule are determined. And the metabolic networks of SHR rats before and after the treatment of the astragalus leech capsule are analyzed by utilizing a metabonomics technology, and the regulation and control of the drug on the overall function of the essential hypertension rat model are systematically explained.
First, experimental material
1. Instrument for measuring the position of a moving object
A constant temperature type noninvasive blood pressure measuring instrument (ZH200, anhuizhua bio instruments ltd); ultra high performance liquid chromatography (Acquity UPLC, Waters corporation, usa); high resolution mass spectrometer (Synapt G2/Si-HDMS, Waters, USA); omics data processing software Progenisis QI (Waters corporation, usa).
2. Reagent
Astragalus leech capsule (provided by Harbin four Chinese medicine factories), aspirin effervescent tablet (specification 0.1g, Aslicon pharmaceutical Co., Ltd.), sodium carboxymethylcellulose (Tanskin Seisaku Seisakusho chemical Co., Ltd.).
3. Laboratory animal
Essential hypertensive rat (SHR), male; the normal blood pressure control animals of WKY rat, male and SHR, which are control strains of hypertensive rat, are provided by Beijing Wintolite laboratory animal technology GmbH, license number: SCXK (Kyoto) 2016-. The breeding temperature is 24 +/-2 ℃, the humidity is 65-75%, the light is shielded for 12 hours, the illumination is carried out for 12 hours, and drinking water is freely taken.
Second, Experimental methods
1. Preparation of dosing samples
1.1 preparation of Astragalus leech capsule medicine gastric juice
Weighing three parts of fine powder of astragalus and leech capsule contents: 32.4g, 64.8g and 129.6g are respectively and uniformly mixed with 1000mL of sodium carboxymethylcellulose (CMC-Na) solution to prepare the astragalus-leech capsule medicament gastric juice with the concentration of 32.4mg/mL, 64.8mg/mL and 129.6mg/mL, which are respectively 1, 2 and 4 times of the dose approved by the astragalus-leech capsule for clinically treating the hyperlipoidemia.
1.2 preparation of Aspirin gastric juice
The common dosage of aspirin anticoagulant is 100 mg/day, and 2 times of the dosage is converted into the administration dosage of rats to prepare aspirin gastric perfusion. 36 aspirin effervescent tablets (each tablet contains 0.1g of aspirin) are taken and put into 20mL of distilled water, after the aspirin effervescent tablets are completely dissolved, CMC-Na solution is slowly added, the mixture is continuously stirred until the solution is uniform, the volume is fixed to 1000mL, and the aspirin gastric juice with the concentration of 3.6mg/mL is prepared.
2. Grouping and administration of laboratory animals
40 male SHR rats, randomly divided into 5 groups of 8: model control group, high-dose administration group of astragalus leech capsule, medium-dose administration group of astragalus leech capsule, low-dose administration group of astragalus leech capsule and aspirin administration group. Male WKY rats 8 were normal controls only. Rats in each group started on a normal diet from the 4 th week of age; starting from the age of 13 weeks, rats in each administration group are intragastrically administered with the corresponding drug by a gastric lavage fluid according to 1.0mL/100g, and are continuously administered for 4 weeks, and rats in a normal control group and a model control group are intragastrically administered with the corresponding dose of CMC-Na solution. The normal control group was WKY rats, male.
3. Measurement of blood pressure and body weight
The systolic pressure is measured noninvasively by adopting a rat tail artery blood pressure analysis system. The rats of the normal control group and the model control group measure the systolic pressure and the body weight of the tail artery every week from the age of 4 weeks; the tail arterial systolic pressure and body weight of rats of each administration group were measured from week 13.
4. Determination of urine metabolic network
4.1 urine sample Collection and processing
Rats 14-17 weeks old were collected overnight for 12 hours urine weekly, centrifuged (4 ℃, 13000r/min, 10min), and stored at-80 ℃. The samples were thawed at room temperature for analysis, diluted 1-fold with distilled water, vortexed for 10s, centrifuged (4 ℃, 13000r/min, 10min), and the supernatant was taken for UPLC-G2-Si-HDMS analysis.
4.2 conditions of analysis
4.2.1 chromatographic conditions
A chromatographic column: waters ACQUITY UPLCTMHST 3(100 mm. times.2.1 mm, 1.8 μm); mobile phase A: 0.1% formic acid in acetonitrile, mobile phase B: 0.1% aqueous formic acid, linear gradient elution procedure is shown in table 1; column temperature: 45 ℃; sample introduction amount: 1 μ L.
TABLE 1 UPLC mobile phase gradient elution method for rat urine samples
4.2.2 Mass Spectrometry conditions
Electrospray ion source (ESI); capillary voltage 2500V; the taper hole voltage is 40V; ion source temperature: 110 ℃; extracting the voltage of the taper hole to be 5.0V; the temperature of desolventizing gas is 400 ℃; the flow rate of the taper hole is 50L/h; the desolventizing agent gas flow is 800L/h; leucine-enkephalin is adopted for accurate mass measurement; mass scan range: 50-1200 Da.
Second, experimental results
1. Changes in blood pressure
The change in systolic blood pressure of rats in the model group before the administration of the drug and the normal control group is shown in Table 2 and FIG. 1. The systolic pressure of the rats in the normal control group is not obviously changed within the age of 4-13 weeks; compared with the normal control group rats, the model group rats have significantly higher systolic pressure from 5 weeks of age than the normal control group (P <0.01) and reach 193.15 +/-4.52 mmHg by 13 weeks of age.
Table 2 rat 4-13 weeks old systolic blood pressure (mmHg) change (mean ± standard deviation, n ═ 8)
Note: p <0.05, P < 0.01.
The blood pressure changes of the model group and the normal control group after the administration of the treatment are shown in Table 3 and FIG. 2. The systolic pressure of the rats in the model group aged 13-17 weeks is continuously increased, and the average systolic pressure at the age of 17 weeks is 202.41 +/-3.35 mmHg; the normal control group rats have no obvious change of systolic pressure, and the average systolic pressure is 128.33 +/-5.68 mmHg. In each administration group, the high, medium and low doses of the astragalus leech capsule can obviously reduce the systolic pressure of rats, and after one week of administration, the astragalus leech capsule has obvious curative effect, and the systolic pressure of three groups of rats is obviously reduced compared with that of a model group (P is less than 0.01). The high-dose antihypertensive effect of the astragalus-leech capsule is the best, the high-dose antihypertensive effect is obviously lower than that of a model group (P <0.01) when the astragalus-leech capsule is treated for 1 week, and the average systolic pressure is reduced to 163.75 +/-9.95 mmHg when the astragalus-leech capsule is administered for 4 weeks; the blood pressure reducing effect of the astragalus-leech capsule dose is only second to the high dose, the blood pressure reducing effect is obviously lower than that of a model group (P <0.01) when the astragalus-leech capsule is treated for 1 week, and the average systolic pressure of rats is reduced to 165.83 +/-7.37 mmHg when the astragalus-leech capsule is administered for 4 weeks; the low-dose antihypertensive effect of the astragalus-leech capsule is not as good as that of the high-dose and medium-dose capsules, but the systolic pressure (P is less than 0.01) of rats is remarkably reduced after 1 week of treatment, and the mean systolic pressure is reduced to 174.83 +/-3.77 mmHg after 4 weeks of treatment. Compared with the model group, the aspirin control group has no significant difference in systolic pressure at 2 weeks of treatment, the systolic pressure at 3 weeks and 4 weeks of treatment is significantly lower than that of the model group (P <0.01), and the mean systolic pressure at 4 weeks of treatment is reduced to 190.16 +/-1.57 mmHg. The result shows that aspirin with the pharmacological effects of inhibiting platelet aggregation and resisting thrombus can not effectively reduce blood pressure, and the traditional Chinese medicine compound astragalus and leech capsule with the functions of tonifying qi, removing blood stasis and dredging collaterals can effectively reduce blood pressure, and shows that the astragalus and leech capsule has a special blood pressure reducing effect.
TABLE 313-17 weeks old rat systolic blood pressure (mmHg) variation comparison (mean. + -. standard deviation, n ═ 8)
Note: p <0.05, P <0.01, compared to normal controls; compared with the model control group, # P <0.05, # P < 0.01.
2. Weight change
The body weight changes of rats in the model group before the administration of the drug and the normal control group are shown in Table 4 and FIG. 3. The weight of the model group rats steadily increases at 5-10 weeks of age, the growth rate is higher than that of the blank group, the growth rate of the model group rats decreases at 10 weeks of age, and the weight of the model group rats is obviously lower than that of the blank group at 13 weeks of age.
Table 4 comparison of body weight (g) changes at 4-13 weeks of age for each group of rats (mean ± sd, n ═ 8)
Note: p <0.05, P <0.01 compared to normal controls.
The body weight changes of rats in the model group and the normal control group after the administration of the treatment are shown in Table 5 and FIG. 4. At the beginning of 13-week-old administration, the body weight of each rat in the administration group is not significantly different from that of the model group, and is in the range of 244.46 +/-9.40 g, which is significantly lower than that of the normal control group rats (P < 0.01). The weight growth rate of rats of 13-17 weeks old and each administration group of the astragalus-leech capsule is higher than that of the model group, and tends to a normal control group. At the age of 17 weeks, the weight of the rats in each administration dose group of the astragalus-leech capsule is higher than that of the model group, has very significant difference (P is less than 0.01), and is close to that of a normal control group. The body weight of the 13-17 week-old aspirin administration group rats is not obviously different from that of the model group.
Table 5 comparison of body weight (g) changes at 13-17 weeks of age in each group of rats (mean ± sd, n ═ 8)
Note: p <0.05, P <0.01, compared to normal controls; compared to the model group, # P <0.05, # P < 0.01.
3. Regulation and control of primary hypertension rat metabolic network
The blood pressure reduction measurement result shows that the high-dose astragalus-leech capsule has a better blood pressure reduction effect, and in order to show the change of a rat metabolic network more clearly, a high-dose astragalus-leech capsule group, a model control group and a blank control group are selected for metabolic network analysis. Analyzing urine at week 17 of high dose group, model control group and normal control group of Astragalus leech capsule by using urine metabolite fingerprint analysis conditions to obtain UPLC-Q/TOF-MS data of rat urine of each group, extracting metabolite retention time, m/z and peak intensity data by using omics data processing software Progenetics QI (Waters, USA), and performing Principal Component Analysis (PCA) to obtain score map (Scores Plot) reflecting organism metabolic network change as shown in figure 5. Each point in the diagram represents each rat, and the position of each point in the diagram represents the spatial state of the metabolic network of the rat; in the figure, point C represents a normal control group rat, point M represents a model control group rat, point QH represents a astragalus leech capsule high-dose group rat, the point C and the point QH can be seen to be gathered into one type, and the point M is gathered into one type, which shows that the disordered metabolic network of the hypertensive rat is adjusted back to the normal rat after the astragalus leech capsule is used for treating, so that the physiological function of an organism can be recovered to a normal level while the astragalus leech capsule is used for reducing blood pressure, and the astragalus leech capsule not only can reduce blood pressure, but also can recover the whole physiological function of the organism by combining with the change of the weight of the rat.
Fourth, conclusion
The research utilizes an essential hypertension rat model to evaluate the treatment effect of the astragalus leech capsule on hypertension, and shows that the astragalus leech capsule can obviously reduce the blood pressure of essential hypertension rats, obviously increase the body weight of the hypertension rats, and call back the metabolic network of the organism of the hypertension rats, so that the essential hypertension can be effectively treated, and the integral physiological function of hypertension can be regulated.
Example 2:
this example differs from example 1 only in that: the astragalus-leech capsule is prepared from the following raw material medicines in parts by weight: 100 parts of astragalus, 40 parts of leech, 75 parts of peach kernel, 75 parts of fleece-flower root, 55 parts of zedoary, 55 parts of rhizoma sparganii, 62.5 parts of cassia seed, 62.5 parts of hawthorn and 15 parts of ground beetle.
Example 3:
this example differs from example 1 only in that: the astragalus-leech capsule is prepared from the following raw material medicines in parts by weight: 400 parts of astragalus, 160 parts of leech, 300 parts of peach kernel, 300 parts of fleece-flower root, 20 parts of zedoary, 220 parts of rhizoma sparganii, 250 parts of cassia seed, 250 parts of hawthorn and 60 parts of ground beetle.
The foregoing shows and describes the general principles, essential features, and advantages of the invention. It will be understood by those skilled in the art that the present invention is not limited to the embodiments described above, which are described in the specification and illustrated only to illustrate the principle of the present invention, but that various changes and modifications may be made therein without departing from the spirit and scope of the present invention, which fall within the scope of the invention as claimed. The scope of the invention is defined by the appended claims and equivalents thereof.
Claims (10)
1. A new use of QIZHI Capsule in preparing medicine for treating essential hypertension is provided.
2. The new use according to claim 1, characterized in that: the astragalus leech capsule can obviously reduce the systolic blood pressure of the essential hypertension.
3. The new use according to claim 2, characterized in that: the astragalus leech capsule can regulate the physiological function of the organism of the essential hypertension.
4. The new use according to claim 3, characterized in that: the physiological functions of the organism comprise weight gain and metabolic rate regulation.
5. The new use according to claim 1, characterized in that: the dosage of the astragalus-leech capsule is 1-4 times of the dosage of the astragalus-leech capsule for clinically treating hyperlipemia.
6. The new use according to claim 1, characterized in that: the astragalus-leech capsule is prepared from the following raw material medicines in parts by weight: 100-400 parts of astragalus membranaceus, 40-160 parts of leech, 75-300 parts of peach kernel, 75-300 parts of polygonum multiflorum, 55-220 parts of curcuma zedoary, 55-220 parts of rhizoma sparganii, 62.5-250 parts of semen cassiae, 62.5-250 parts of hawthorn and 15-60 parts of ground beetle.
7. The new use according to claim 1, characterized in that: the astragalus and leech capsule comprises 200 parts of astragalus, 80 parts of leech, 150 parts of peach kernel, 150 parts of polygonum multiflorum, 110 parts of curcuma zedoary, 110 parts of rhizoma sparganii, 125 parts of cassia seed, 125 parts of hawthorn and 30 parts of ground beetle.
8. The new use according to claim 6 or 7, characterized in that: the preparation method of the astragalus-leech capsule comprises the following steps:
step one, weighing leeches, curcuma zedoary and rhizoma sparganii according to a proportion, and crushing into fine powder;
step two, weighing the astragalus, the peach kernel, the polygonum multiflorum, the cassia seed, the hawthorn and the ground beetle according to the proportion, adding water for decocting twice, adding 10 times of water for the first time, adding 8 times of water for the second time, decocting for 2 hours each time, combining decoction liquids, filtering, and concentrating the filtrate to thick paste with the relative density of 1.30-1.35;
and step three, adding the fine powder obtained in the step one into the thick paste obtained in the step two, uniformly mixing, drying at 50-60 ℃, crushing, and encapsulating to obtain the capsule.
9. The new use according to claim 8, characterized in that: the relative density of 1.30 to 1.35 is a relative density at 80 ℃.
10. The new use according to claim 8, characterized in that: the formulation of the astragalus-leech capsule can be replaced by granules, tablets, powder or pills.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110641504.1A CN113368209B (en) | 2021-06-09 | 2021-06-09 | New use of QIZHI Capsule in preparing medicine for treating essential hypertension |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110641504.1A CN113368209B (en) | 2021-06-09 | 2021-06-09 | New use of QIZHI Capsule in preparing medicine for treating essential hypertension |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113368209A true CN113368209A (en) | 2021-09-10 |
| CN113368209B CN113368209B (en) | 2023-07-11 |
Family
ID=77573061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110641504.1A Active CN113368209B (en) | 2021-06-09 | 2021-06-09 | New use of QIZHI Capsule in preparing medicine for treating essential hypertension |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113368209B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1391915A (en) * | 2001-06-15 | 2003-01-22 | 刘宇晖 | Chouxue qing capsule for reducing blood viscosity |
-
2021
- 2021-06-09 CN CN202110641504.1A patent/CN113368209B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1391915A (en) * | 2001-06-15 | 2003-01-22 | 刘宇晖 | Chouxue qing capsule for reducing blood viscosity |
Non-Patent Citations (1)
| Title |
|---|
| 田学增等: "芪蛭胶囊治疗冠心病心绞痛临床观察", 《中医药学报》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113368209B (en) | 2023-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100455291C (en) | Notoginseng medicine composition for treating cardiac and cerebral vascular diseases | |
| CN111110824B (en) | Medicinal composition for strengthening body resistance and rescuing lung and application thereof | |
| CN103989668A (en) | Application of fructus forsythiae aglycone in preparing medicament for preventing or treating liver injury or liver failure | |
| WO2021204170A1 (en) | Active peptide derived from eupolyphaga sinensis walker and having blood lipid lowering function, and preparation method therefor and use thereof | |
| CN114246918B (en) | Traditional Chinese medicine composition for treating hashimoto thyroiditis and preparation method thereof | |
| CN109125315A (en) | Composition and purposes with hypoglycemic, reducing blood lipid and hypotensive activity | |
| Chun et al. | Effect of antacids on absorption of clorazepate | |
| CN100467025C (en) | Use of asiaticoside in preparation of medicines for diseases of cardio-cerebral blood vessels | |
| CN1931233B (en) | Medicine composition of red sage and epimedium for treating cardiac and cerebral vascular diseases | |
| CN113368209A (en) | New application of astragalus-leech capsule in preparation of medicine for treating primary hypertension | |
| CN106063791A (en) | The application in preparing anti-inflammatory drug of the compositions of phillyrin, phillyrin derivant, phillyrin and phillygenol | |
| CN109381455A (en) | With the composition for adjusting blood glucose, blood lipid and blood pressure function | |
| CN101450117B (en) | Rheumatism treatment medicine composition, formulation and preparation method | |
| CN101396435B (en) | Traditional Chinese medicine for treating gastrosis and preparation method and use thereof | |
| CN1331466C (en) | Medicine preparation for treating liver and gallbladder disease and its preparing process | |
| CN104688723A (en) | Application of anhydroicaritin in preparation of medicine for treating anaemia | |
| CN111166759A (en) | A pharmaceutical composition for treating coronary heart disease | |
| CN108057102B (en) | Pharmaceutical composition for preventing or treating gouty arthritis, preparation method and application | |
| CN104042613B (en) | A kind of composition and the purposes in medicine thereof | |
| CN114558047B (en) | Traditional Chinese medicine composition for preventing and treating osteoporosis and preparation method thereof | |
| CN115243774B (en) | Pharmaceutical composition containing amlodipine, chlorthalidone and amiloride | |
| CN114028449B (en) | Traditional Chinese medicine compound medicine for treating fatty liver disease | |
| CN115337348B (en) | Traditional Chinese medicine composition for treating heat-accumulation blood vessels | |
| CN1575803A (en) | Application method of Aloe vera L. extract in preventing and curing diabetes | |
| CN107213323B (en) | Chinese medicinal compound preparation for nourishing yin, eliminating phlegm, resolving masses and detoxifying and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231030 Address after: 150025 North Nanjing Road, Limin Development Zone, Harbin City, Heilongjiang Province Patentee after: Harbin traditional Chinese medicine four factory Co.,Ltd. Address before: 150025 Harbin No.4 traditional Chinese Medicine Factory Co., Ltd., north of Nanjing Road, Limin Development Zone, Harbin, Heilongjiang Province Patentee before: Che Yanning |
|
| TR01 | Transfer of patent right |